Septerna, Inc.
SEPNNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $46.0M | $1.1M | $151,000 |
| Operating income | −$68.3M | −$80.8M | $2.1M |
| Net income | −$48.9M | −$71.8M | $4.2M |
| Total assets | $596.2M | $456.6M | $130.9M |
| Total liabilities | $214.3M | $36.5M | $20.0M |
| Equity | $381.9M | $420.0M | −$38.4M |
| EPS (diluted) | $-1.10 | $-7.26 | $0.29 |
| Shares out. | 44.4M | 44.4M | 3.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −148.6%
- Net margin
- −106.4%
- Return on equity
- −12.8%
- Return on assets
- −8.2%
- Return on capital (ROCE)
- −13.4%
- Liabilities / assets
- 35.9%
- Debt / equity
- 0.56×
- Book value / share
- $8.59
- Revenue growth (YoY)
- 4174.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.75safe
- Accruals / assets
- −26.7%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 5 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Shaikhly SamiraOfficer — Chief People Officer | May 26, 2026 | Option exercise | 11,798 | $6.81 |
| Bhatt ElizabethOfficer — President and COO | Apr 15, 2026 | Option exercise | 4,000 | $6.81 |
| Shaikhly SamiraOfficer — Chief People Officer | Mar 2, 2026 | Option exercise | 53,714 | $1.55 |
| Bhatt ElizabethOfficer — President and COO | Feb 18, 2026 | Option exercise | 4,000 | $6.81 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.4M | 7.4 | +15.6% |
| Apr 30, 2026 | 2.1M | 5.4 | -15.9% |
| Apr 15, 2026 | 2.5M | 8.1 | +12.9% |
| Mar 31, 2026 | 2.2M | 8.7 | +4.8% |
| Mar 13, 2026 | 2.1M | 6.3 | +12.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Regulation FD disclosureApr 13, 2026
- Results of operationsMar 9, 2026
- Regulation FD disclosure · Other material eventMar 2, 2026
- Regulation FD disclosureJan 12, 2026
- Regulation FD disclosureJan 8, 2026
- Results of operationsNov 10, 2025
- Director / officer change · Regulation FD disclosureSep 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.